Richard J Himmelsbach

US Patent:

20100297778, Nov 25, 2010

Filed:

May 20, 2009

Appl. No.:

12/468939

Inventors:

John G. Konrath - Lake Villa IL, US
Jeffrey A. Moore - Gurnee IL, US
Richard J. Himmelsbach - Libertyville IL, US

Assignee:

Abbott Laboratories - Abbott Park IL

International Classification:

G01N 33/566
C07K 16/18

US Classification:

436501, 5303913

Abstract:

A method and reagent that can be used to eliminate the signal caused by non-specific binding of a labeled conjugate, e.g., a specific binding member attached to a label, to a solid phase, e.g., a magnetic microparticle. The method and the reagent involve the use of a cleavable linking agent to link the label to the specific binding member that specifically binds to the analyte. The use of a cleavable linking agent would allow the release of the label from the specific binding member from the complex comprising the magnetic microparticle, analyte, and labeled conjugate into solution. After the release of the label, the magnetic microparticles having any label non-specifically bound thereto, are removed from the reaction mixture. Only the label, e.g., acridinium, from the labeled conjugate would remain in the elution well. The conjugate that is non-specifically bound through interaction between the label and the solid phase, e.g., a magnetic particle, would remain bound to the solid phase, and would subsequently be removed from the elution well when the solid phase is removed from the elution well and transferred to another well the introduction of additional reagent(s).

US Patent:

58696512, Feb 9, 1999

Filed:

Aug 8, 1994

Appl. No.:

8/190143

Inventors:

Richard J. Himmelsbach - Pleasanton CA
P.ang.l Rongved - Hellvik, NO
Jo Klaveness - Oslo, NO
Per Strande - Oslo, NO
Harald Dugstad - Oslo, NO

Assignee:

Nycomed Salutar - Sunnyvale CA

International Classification:

C07D49808
C07F 1502

US Classification:

540474

Abstract:

The invention relates to certain substituted derivatives of aminopolycarboxylic acids and metal chelates thereof. The compounds are particularly suitable for use as diagnostic agent. For example, the compounds can be used as radiodiagnostic agents, detoxification agents and contrast agents for diagnostic imaging processes. In particular, the high relaxivity paramagnetic metal chelates of substituted aminopolycarboxylic acids are especially suited for use as magnetic resonance imaging contrast agents.

US Patent:

50360531, Jul 30, 1991

Filed:

Mar 15, 1989

Appl. No.:

7/321638

Inventors:

Richard Himmelsbach - San Jose CA
John C. Hodges - Ann Arbor MI
James S. Kaltenbronn - Ann Arbor MI
William C. Patt - Chelsea MI
Joseph T. Repine - Ann Arbor MI
Ila Sircar - Ann Arbor MI

Assignee:

Warner-Lambert Company - Morris Plains NJ

International Classification:

A61K 3702

US Classification:

514 19

Abstract:

The invention concerns novel renin-inhibitory peptides which are useful for treating renin-associated hypertension, congestive heart failure, hyperaldosteronism, and diseases caused by retroviruses including HTLV-I and -III. Processes for preparing the peptides, composition containing them, and methods of using them are included. Also included is a diagnostic method which uses the compounds to determine the presence of renin-associated hypertensions, or hyperaldosteronism.

US Patent:

54461456, Aug 29, 1995

Filed:

Jul 7, 1993

Appl. No.:

8/086996

Inventors:

David B. Love - Campbell CA
William C. Dow - Fremont CA
Richard J. Himmelsbach - Pleasanton CA
Alan D. Watson - Campbell CA
Scott M. Rocklage - Los Gatos CA

Assignee:

Nycomed Salutar, Inc. - Sunnyvale CA

International Classification:

C07D22502

US Classification:

540465

Abstract:

There are disclosed polychelant compounds, that is multi-site metal chelating agents, and chelates formed therewith. The polychelants and especially their paramagnetic metal, heavy metal or radioactive metal polychelates are particularly suitable for use in diagnostic imaging, heavy metal detoxification or radiotherapy. The polychelants have a linear or branched oligomeric structure comprising alternating chelant and linker moieties bound together by amide or ester moieties the carbonyl groups whereof being adjacent the chelant moieties, each polychelant comprising at least two said chelant moieties capable of complexing a metal ion.

US Patent:

52817040, Jan 25, 1994

Filed:

Jan 19, 1990

Appl. No.:

7/468107

Inventors:

David B. Love - Campbell CA
William C. Dow - Fremont CA
Richard J. Himmelsbach - Pleasanton CA
Alan D. Watson - Campbell CA
Scott M. Rocklage - Los Gatos CA

Assignee:

Salutar, Inc. - Sunnyvale CA

International Classification:

C07D25702
C07H 2300
C07H 1512
C07H 1902

US Classification:

540465

Abstract:

There are disclosed polychelant compounds, that is multi-site metal chelating agents, and chelates formed therewith. The polychelants and especially their paramagnetic metal, heavy metal or radioactive metal polychelates are particularly suitable for use in diagnostic imaging, heavy metal detoxification or radiotherapy. The polychelants have a linear or branched oligomeric structure comprising alternating chelant and linker moieties bound together by amide or ester moieties the carbonyl groups whereof being adjacent the chelant moieties, each polychelant comprising at least two said chelant moieties capable of complexing a metal ion.

US Patent:

52602788, Nov 9, 1993

Filed:

Apr 1, 1991

Appl. No.:

7/678469

Inventors:

Richard Himmelsbach - San Jose CA
John C. Hodges - Ann Arbor MI
James S. Kaltenbronn - Ann Arbor MI
William C. Patt - Chelsea MI
Joseph T. Repine - Ann Arbor MI
Ila Sircar - Ann Arbor MI

Assignee:

Warner-Lambert Company - Morris Plains NJ

International Classification:

A61K 3702
C07D26530
C07D29526
C07K 506

US Classification:

514 19

Abstract:

The invention concerns novel renin-inhibitory peptides which are useful for treating renin-associated hypertension, congestive heart failure, hyperaldosteronism, and diseases caused by retroviruses including HTLV-I and -III. Processes for preparing the peptides, compositions containing them, and methods of using them are included. Also included is a diagnostic method which uses the compounds to determine the presence of renin-associated hypertension, or hyperaldosteronism.